PSTI Pluristem Therapeutics, Inc.

1.37
0  -1%
Previous Close 1.39
Open 1.38
Price To book 4.50
Market Cap 131.61M
Shares 96,065,000
Volume 112,603
Short Ratio 2.14
Av. Daily Volume 372,232

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment to commence 1H 2017.
PLX-PAD (stem cells)
Critical limb ischemia (CLI)
Phase 2 put on clinical hold Jun 2013. Lifted Sept 2013. Enrollment completed May 2016. Data are due late 2017.
PLX-PAD (stem cells)
Intermittent claudication, or IC

SEC Filings

  1. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17726549
  2. DEF 14A - Other definitive proxy statements 17726302
  3. 8-K - Current report 17725927
  4. 8-K - Current report 17722370
  5. 10-Q - Quarterly report (Sections 13 or 15(d)) 17582564
  6. 8-K - Current report 17538846
  7. 424B5 - Prospectus (Rule 424(b)(5)) 17537498
  8. 424B5 - Prospectus (Rule 424(b)(5)) 17536594
  9. 8-K - Current report 17529664
  10. 8-K - Current report 17522298